India’s healthcare industry has entered a decisive growth phase, marked by accelerating consolidation, rising capital deployment, and a clear pivot toward high-acuity care. According to EY-Parthenon’s Q2 FY26 sector update, the industry recorded more than Rs 10,000 crore in mergers and acquisitions during the quarter, making it one of the strongest deal periods in recent years. The momentum cuts across hospitals, diagnostics, specialty care, and medical technology, reflecting both operational strength and investor conviction in the sector’s long-term demand profile.

India’s healthcare sector has been on a structural growth path for over a decade, driven by demographic shifts, rising lifestyle diseases, expanding insurance coverage, and higher out-of-pocket spending. However, the post-pandemic period has fundamentally altered demand dynamics. Hospitals are seeing a sustained rise in complex clinical cases, while diagnostics players are benefiting from increased awareness, preventive testing, and advanced molecular and genomics-based diagnostics.

Against this backdrop, private equity funds and strategic investors have steadily increased exposure to healthcare assets, particularly scalable regional platforms and integrated care models. The Q2 FY26 numbers indicate that this interest has not only persisted but intensified, despite premium valuations.

The most significant shift underway is the sector’s aggressive capacity build-out and focus on high-end clinical specialties. Large hospital networks plan to add over 18,000 beds over the next three to five years, marking the most ambitious expansion cycle the industry has seen. High-acuity segments such as oncology, cardiology, neurology, and gastroenterology are driving patient volumes as well as pricing power.

EY-Parthenon data shows that average revenue per occupied bed rose between 10% and 16% year-on-year among large hospital chains. This improvement is being supported by higher case complexity, better clinical mix, and tighter pricing discipline rather than volume-led discounting.

At the same time, diagnostics chains continue to outperform. Revenue growth of 10% to 22% was recorded across major players, with EBITDA margins ranging from 25% to 35%. Scale efficiencies, automation, and a rapid shift toward oncology diagnostics, molecular testing, and genomics have materially improved profitability. Preventive and wellness packages now contribute up to 26% of quarterly revenues for some diagnostics operators, underscoring the structural rise in consumer-led healthcare spending.

For investors and policymakers, this cycle signals that Indian healthcare is no longer just a defensive play. The sector is transitioning into a growth-driven industry with expanding margins, capital efficiency, and export potential through medical tourism and overseas acquisitions.

Large listed hospital chains such as Apollo Hospitals Enterprise, Max Healthcare Institute, Aster DM Healthcare, Narayana Hrudayalaya, and Krishna Institute of Medical Sciences have reported double-digit revenue growth, stable to rising occupancies, and improving international patient inflows. Digital health and home-care services are also emerging as meaningful contributors, accounting for as much as 25%–30% of revenue for some operators.

From a system-level perspective, the push into Tier-2, Tier-3, and even Tier-4 cities addresses India’s chronic healthcare access gap while creating long runways for growth beyond metro saturation.

EY-Parthenon described Q2 FY26 as confirmation of the sector’s structural strength. Kaivaan Movdawalla, National Healthcare Leader at EY-Parthenon, highlighted the shift toward high-acuity care and advanced diagnostics as evidence of durable, long-term growth drivers. Separately, EY noted that while new assets may face short-term margin pressure during ramp-up, medium-term fundamentals remain robust.

The deal environment reflects this confidence. Manipal Hospitals’ Rs 5,300 crore buyout of Sahyadri Hospitals from OTPP, Baby Memorial Hospital’s majority acquisition of Meitra Hospital for Rs 1,000–1,200 crore, and Fortis Healthcare’s Rs 470 crore acquisition of Shrimann Hospitals point to rapid regional consolidation. Meanwhile, Narayana Hrudayalaya’s £183 million acquisition of Practice Plus Group Hospitals marks a strategic overseas expansion, highlighting Indian operators’ growing global ambitions.

Valuations remain elevated, with listed healthcare companies trading at EV/EBITDA multiples ranging from the mid-teens to over 30x. Investors appear willing to pay premiums for integrated platforms, strong unit economics, and technology-enabled models.